$16.22+3.22 (+24.77%)
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
Apollomics, Inc. in the Healthcare sector is trading at $16.22. The stock is currently 61% below its 52-week high of $42.12, remaining 4.0% above its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why APLM maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio inclu...